KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Payables (2017 - 2026)

Aquestive Therapeutics has reported Payables over the past 9 years, most recently at $29.9 million for Q4 2025.

  • For Q4 2025, Payables rose 190.29% year-over-year to $29.9 million; the TTM value through Dec 2025 reached $29.9 million, up 190.29%, while the annual FY2025 figure was $29.9 million, 190.29% up from the prior year.
  • Payables for Q4 2025 was $29.9 million at Aquestive Therapeutics, up from $10.9 million in the prior quarter.
  • Over five years, Payables peaked at $29.9 million in Q4 2025 and troughed at $5.7 million in Q2 2024.
  • A 5-year average of $10.4 million and a median of $10.0 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: crashed 59.21% in 2021 and later soared 190.29% in 2025.
  • Year by year, Payables stood at $8.3 million in 2021, then increased by 19.63% to $9.9 million in 2022, then dropped by 10.26% to $8.9 million in 2023, then increased by 15.25% to $10.3 million in 2024, then soared by 190.29% to $29.9 million in 2025.
  • Business Quant data shows Payables for AQST at $29.9 million in Q4 2025, $10.9 million in Q3 2025, and $12.0 million in Q2 2025.